Nitrosamines: Navigating the Evolving Regulatory Landscape in India

St, 18.11.2026 07:00 CET
Získejte praktické návody na řízení rizik nitrosaminů od Agilent a Indické lékopisné komise. Zabezpečte integritu dat od vývoje po kontrolu kvality.
Agilent Technologies: Nitrosamines: Navigating the Evolving Regulatory Landscape in India
Agilent Technologies: Nitrosamines: Navigating the Evolving Regulatory Landscape in India

INSIDE IMPURITIES: ASK THE EXPERT

Episode 1 | Nitrosamines: Navigating the Evolving Regulatory Landscape in India

The pharmaceutical impurities landscape is evolving — and so are the questions around risk, regulation, testing and control.

Inside Impurities: Ask the Expert is a new expert-led webinar series bringing together regulatory, industry and analytical perspectives on the impurity challenges shaping pharmaceutical development and quality.

We begin with nitrosamines — one of the industry's continuing areas of regulatory and analytical focus.

What does the evolving nitrosamine landscape mean for pharmaceutical manufacturers in India?

As expectations around nitrosamine risk assessment and control continue to evolve, manufacturers need to look beyond end-product testing and consider potential formation pathways, NDSRIs, analytical strategies and regulatory readiness across the product lifecycle.

Join Dr. Arvind Kumar Sharma, Scientific Officer, Indian Pharmacopoeia Commission, in conversation with Dr. Kuldeep Sharma, Pharma Market Development Manager, India, Agilent, for a focused discussion on India's evolving nitrosamine landscape.

What we'll explore
  • India's evolving regulatory approach to nitrosamines and NDSRIs
  • Expectations around risk assessment and control strategies
  • Potential sources and pathways of nitrosamine formation
  • Considerations for trace-level analytical testing
  • Method validation, data integrity and documentation
  • Emerging challenges and practical approaches to nitrosamine management
  • Building regulatory readiness as expectations evolve
Why this matters

For pharmaceutical teams, nitrosamine management is increasingly about more than detecting an impurity. It requires a risk-based understanding of where impurities can form, how they can be controlled, and how the resulting evidence can stand up to regulatory scrutiny.

This session brings the regulatory and industry perspectives together to help you understand what to consider in your own nitrosamine strategy.

Bring your questions

Submit it when you register and our experts may address it during the discussion.

You can also ask questions live during the Q&A session.

Presenter: Arvind Kumar Sharma (Scientific Officer, Indian Pharmacopoeia Commission - Ministry of Health & Family Welfare - Government of India)

With over six years of experience at the Indian Pharmacopoeia Commission, Arvind has contributed to the development of Indian Pharmacopoeia Reference Substances (IPRS), impurity standards, and draft monographs for the Indian Pharmacopoeia (IP). He has also supported the development of the National Formulary of India 2021 and initiatives under the Pharmacovigilance Programme of India (PvPI). He holds an M.Pharm in Pharmacology from Sinhgad Institute of Pharmaceutical Sciences, Pune and has authored international publications, represented IPC at national and international forums. He also participates in joint inspections of manufacturing and testing facilities.

Presenter: Dr. Kuldeep Sharma (Business Development Manager - Pharma, Agilent Technologies)

Dr. Kuldeep Sharma has over 23 years of experience in area of pharmaceuticals analytical R&D, analytical method development and validation, clinical and preclinical studies, and regulatory compliance. His professional journey covers a true blend of technical and commercial industry insight, with a PhD in biotechnology, over 13 years as an analytical research scientist (with leading pharma companies like Zydus Cadila, Lambda, Teva, and Jubilant Biosys), and 10 years as techno-commercial expert leading analytical instruments sales strategies and marketing initiatives.

During his industry experience, he has accomplished leading roles in domains covering analytical research, pharma quality compliance, and preclinical and analytical studies. With over 21 research articles published in international journals and 5 technical write-ups in leading magazines, he presents an attitude of continued learning, enabling him to acquire advance certifications of Lean Six Sigma-Black Belt and MBA (Operations Management) in addition to his professional journey.

Presently, he works as a sales development manager for pharmaceutical markets at Agilent Technologies in India.

Agilent Technologies
LinkedIn Logo